UNSPSC 51242207: Chloroxylenol/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.

UNSPSC 51242207 Chloroxylenol/pramoxine is a Commodity code covering topical antiseptic and anesthetic pharmaceutical products that state and local health agencies and correctional facilities procure through cooperative purchasing vehicles and direct solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body visible in recent activity, sourcing generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions. Vendors supplying under this code must meet FDA compliance requirements, maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA), and establish contractual relationships with authorized pharmaceutical wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Product submissions require National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength specifications, dosage forms, trade names, packaging configurations, and manufacturing locations, with all products available in the marketplace by the effective contract date.

The most recent significant opportunity is MMCAP's multistate RFP S1070000015802, issued January 20, 2026, with proposals due March 26, 2026, establishing multiple contracts for generic pharmaceuticals and OTC products effective July 1, 2026. Vendors must maintain comprehensive insurance coverage including $5 million commercial general liability per occurrence, $2 million network security and privacy liability, and $2 million professional liability, and agree to a 3 percent administrative fee on all purchases with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. Evaluation emphasizes price competitiveness at 75 percent weight, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and fee structure agreement. The RFP does not identify specific set-aside restrictions, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.